

Oncology Today with Dr Neil Love: Gastrointestinal Cancers Edition 2019 — Hepatocellular Carcinoma

Video Program

CME Information

TARGET AUDIENCE

This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastrointestinal cancers.

OVERVIEW OF ACTIVITY

Hepatocellular carcinoma (HCC), the most common form of liver cancer, is the fourth leading cause of cancer-related death worldwide. A rising incidence, multiple etiologies, genetic heterogeneity and concurrent chronic liver disease make the selection of treatment for HCC challenging, and the disease is often diagnosed in the advanced stage, at which it is associated with poor prognosis. Recent breakthroughs in understanding the etiology and pathogenesis have led to the advent of new treatment modalities and investigational therapies. In order to offer optimal patient care, the practicing oncologist must be well informed of these advances.

To bridge the gap between research and patient care, this issue of *Oncology Today with Dr Neil Love* focusing on HCC features a discussion with 2 leading gastrointestinal oncology investigators. By providing access to the latest research developments and expert perspectives on the disease, this CME activity assists medical oncologists and select gastroenterology specialists in the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

- Consider patient age, performance status, liver function and other clinical and logistical factors in the up-front and subsequent management of unresectable or metastatic HCC.
- Appraise recent Phase III data with lenvatinib, and consider its clinical role in the care of patients with previously untreated unresectable HCC.
- Appreciate the recent FDA approval of cabozantinib for patients who have previously received sorafenib, and consider how this agent can be optimally integrated into therapy for these individuals.
- Understand the biologic rationale for immune checkpoint inhibition in the treatment of HCC, and recall available clinical data with approved and investigational checkpoint inhibitors.

- Recognize immune-related adverse events and other common side effects associated with approved and developmental immune checkpoint inhibitors, and offer supportive management strategies to minimize and manage these toxicities.
- Evaluate the latest Phase III data with ramucirumab for patients with advanced HCC and elevated alpha-fetoprotein who previously received sorafenib.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 1.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: **medical oncology**.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at [ResearchToPractice.com/Privacy-Policy](https://www.researchtopractice.com/Privacy-Policy) for more information.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/OncologyTodayGI19/HCC/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/OncologyTodayGI19/HCC.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Anthony El-Khoueiry, MD

Associate Professor of Clinical Medicine
Medical Director of Clinical Investigations Support Office
Phase I Program Director
USC Norris Comprehensive Cancer Center
Los Angeles, California

Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, CytomX Therapeutics, Eisai Inc, EMD Serono Inc, Exelixis Inc, Merck, Pieris Pharmaceuticals Inc; **Consulting Agreements:** Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company; **Contracted Research:** Astex Pharmaceuticals, AstraZeneca Pharmaceuticals LP.

R Kate Kelley, MD

Associate Professor of Clinical Medicine
Department of Medicine (Hematology/Oncology)
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Advisory Committee: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Exelixis Inc; **Consulting Agreements:** AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company; **Contracted Research:** Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, Lilly, Merck, Novartis, QED Therapeutics, Taiho Oncology Inc; **Data and Safety Monitoring Board:** Genentech/Roche Laboratories Inc; **Steering Committee and Publications Committee:** TARGET PharmaSolutions Inc.

MODERATOR — **Dr Love** is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS

— Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Lilly.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later,
Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: February 2019

Expiration date: February 2020

Select Publications

- A phase III, open-label, randomized study of atezolizumab in combination with bevacizumab compared with sorafenib in patients with untreated locally advanced or metastatic hepatocellular carcinoma. NCT03434379**
- Abou-Alfa GK et al. **A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.** *Proc ASCO* 2018;Abstract TPS4144.
- Abou-Alfa GK et al. **Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.** *Gastrointestinal Cancers Symposium* 2018;Abstract 207.
- Abou-Alfa GK et al. **Cabozantinib in patients with advanced and progressing hepatocellular carcinoma.** *N Engl J Med* 2018;379(1):54-63.
- Brar G et al. **Hepatocellular carcinoma (HCC) survival by etiology: A SEER-Medicare database analysis.** *Gastrointestinal Cancers Symposium* 2019;Abstract 201.
- Bruix J et al. **Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial.** *Lancet* 2017;389(10064):56-66.
- Bruix J et al. **Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment.** *Proc ESMO World Congress on Gastrointestinal Cancer* 2017;Abstract O-009.
- Chow PKH et al. **SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma.** *J Clin Oncol* 2018;36(19):1913-21.
- El-Khoueiry AB et al. **Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial.** *Lancet* 2017;389(10088):2492-502.
- Finn R et al. **Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α -fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.** *Gastrointestinal Cancers Symposium* 2019;Abstract 326.
- Finn RS et al. **Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.** *J Hepatol* 2018;69(2):353-8.
- Frenette CT. **The role of regorafenib in hepatocellular carcinoma.** *Clin Adv Hematol Oncol* 2017;15(2):121-3.
- Ikeda M et al. **A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).** *Proc ASCO* 2018;Abstract 4076.
- Kaseb AO et al. **Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.** *Gastrointestinal Cancers Symposium* 2019;Abstract 185.
- Kudo M et al. **Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).** *Gastrointestinal Cancers Symposium* 2019;Abstract 320.
- Kudo M et al. **Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial.** *Lancet* 2018;391(10126):1163-73.
- Llovet JM et al; SHARP Investigators Study Group. **Sorafenib in advanced hepatocellular carcinoma.** *N Engl J Med* 2008;359(4):378-90.
- Okusaka T et al. **Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.** *Gastrointestinal Cancers Symposium* 2019;Abstract 316.
- Personeni N et al. **Liver injury by immune checkpoint inhibitors in patients with hepatocellular carcinoma.** *Gastrointestinal Cancers Symposium* 2019;Abstract 341.
- Thota R et al. **Characterization of the tumor mutation burden in hepatobiliary tumors.** *Gastrointestinal Cancers Symposium* 2019;Abstract 295.
- Vilgrain V et al. **Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial.** *Lancet Oncol* 2017;18(12):1624-36.
- Zhu AX et al. **Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.** *Proc ASCO* 2018;Abstract 4020.

Select Publications

Zhu AX et al. **REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.** *Proc ASCO* 2018;Abstract 4003.

Zhu AX et al; KEYNOTE-224 Investigators. **Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial.** *Lancet Oncol* 2018;19(7):940-52.

Zhu AX et al; REACH Trial Investigators. **Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial.** *Lancet Oncol* 2015;16(7):859-70.